Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T19:15:42.480Z.
Calculation as of: 2026-10-06T19:15:42.480Z.
Quote observation: 2026-10-06T19:14:59.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ce14650c18fa49a41504767bbd6ec089d5034b69e4d808542ce8aeb5b63776d1
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
ALX Oncology Holdings Inc.
Market Cap
$148.69M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$148.48M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$149.28M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$147.35M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$147.34M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$147.13M
Price/OCF Ratio
N/A
TTM Avg
11.71
3Y Avg
27.68
5Y Avg
23.05
Market Cap
$146.71M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$145.29M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ALX Oncology Holdings Inc. (ALXO) | $148.69M | N/A | N/A | N/A | N/A |
| Veraxa Biotech Holding AG (VRXA)vs › | $148.48M | N/A | N/A | N/A | N/A |
| Codexis, Inc. (CDXS)vs › | $148.97M | N/A | 32.64 | 32.64 | 32.64 |
| Cardiol Therapeutics Inc. (CRDL)vs › | $149.28M | N/A | N/A | N/A | N/A |
| Anavex Life Sciences Corp. (AVXL)vs › | $147.35M | N/A | N/A | N/A | N/A |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $147.34M | N/A | N/A | N/A | N/A |
| Voyager Therapeutics, Inc. (VYGR)vs › | $147.13M | N/A | 11.71 | 27.68 | 23.05 |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $146.71M | N/A | N/A | N/A | N/A |
| Protara Therapeutics, Inc. (TARA)vs › | $145.29M | N/A | N/A | N/A | N/A |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $152.82M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
